The FDA approved Novo Nordisk’s once-weekly basal insulin Awiqli (insulin icodec) injection 700 units/mL, clearing a long-awaited shift from daily insulin regimens for type 2 diabetes. Novo’s product becomes the first and only once-weekly long-acting basal insulin option approved for this indication in the U.S. The decision continues a race to improve adherence and simplify chronic diabetes management, with weekly formulations aiming to reduce treatment burden. For providers and payers, it also raises new reimbursement and formulary considerations around dosing cadence and patient selection. The approval follows extensive regulatory review after Novo began building clinical and regulatory momentum across multiple territories for the weekly basal approach.